Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device

A Phase 3, 12-Week, Parallel-Design Study Comparing The Safety, Efficacy, and Ease Of Use Of Xalatan When Self-Administered By Subjects With Open-Angle Glaucoma Or Ocular Hypertension Using Either A Conventional Dropper Bottle Or A Forced-Flow Delivery Device

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00283764

Enrollment

Registered

2006-01-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Open-Angle, Ocular Hypertension

Brief summary

Compare the antihypertensive efficacy of two methods for instilling Xalatan eyedrops

Interventions

DRUGXalatan

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes

Exclusion criteria

* History of closed/barely open anterior chamber angle or a history of angle closure

Design outcomes

Primary

Measure	Time frame
Intra-ocular pressure (IOP) level in the study eye.	—

Secondary

Measure	Time frame
Successful eyedrop self-deliveries	—
Ease of eyedrop administration	—
Change in safety assessments throughout the study period	—
Subject preference for the method of drop delivery	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026